Stanfield Capital

Stanfield Capital

Stanfield Capital was founded in December 2014 by Managing Partner Troy L. Stanfield. Stanfield brought over a decade of lower middle market consumer experience from Castanea Partners, a $600M consumer-focused private equity firm he joined at its 2002 launch. Prior to Castanea, he worked at Bain & Company and Berkshire Partners, building a career concentrated on consumer products and retail. The firm invests in lower middle market consumer companies with $10–$100 million in revenue and $2–$10 million in EBITDA. Deal types span majority, minority, growth equity, leveraged buyouts, and turnaround situations. Stanfield targets businesses at inflection points where its operating approach and network can surface incremental value. To date, the firm has deployed $22 million of equity across three transactions, with the combined portfolio generating approximately $130 million in annual revenue and $15 million in EBITDA (per firm website). The firm operates from a single office in Needham, Massachusetts, originating and managing investments across the United States. Stanfield Capital operates with a lean structure led by its founder. The website does not list additional investment professionals, and no adjacent vehicles — such as credit funds, real asset arms, or philanthropic foundations — are disclosed. The firm’s current posture is defined by its deployment history: over roughly a decade, it has averaged just under one new platform investment every three years, signaling high selectivity and an emphasis on intensive post-close involvement. The firm has not publicly announced new transactions or team changes in the last 24 months. The firm’s architecture is distinguished by its constraint: a single decision-maker deploying his own firm's committed capital into a narrow consumer band. Stanfield does not market fund vintages, solicit co-investors on its website, or describe a formal LP base. This suggests a model closer to an independent sponsor or small pledged-capital vehicle than a blind-pool fund, a structure that allows patient deal pacing but limits third-party capital formation visibility.